APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Platinum-based Antineoplastic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Platinum-based Antineoplastic Market Outlook and Growth Opportunities 2026

Report ID 174026670430 December 2025193 pages

Choose your research edition.

Industry ResearchPlatinum-based Antineoplastic Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Platinum-based Antineoplastic Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Platinum-based Antineoplastic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Platinum-based Antineoplastic Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Platinum-based Antineoplastic Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Platinum-based Antineoplastic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Platinum-based Antineoplastic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Platinum-based Antineoplastic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Platinum-based Antineoplastic market include ChiTaiTianQing Pharmaceutical Group, Simcere Pharmaceutical, CSPC Pharmaceutical Group, Sanofi, Novartis, MSD, Roche, Pfizer and Hengrui Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Platinum-based Antineoplastic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Platinum-based Antineoplastic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Platinum-based Antineoplastic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Platinum-based Antineoplastic market size, projected growth trends, production technologies, key applications, and end-use industries.

Platinum-based Antineoplastic Segment by Company

ChiTaiTianQing Pharmaceutical Group

Simcere Pharmaceutical

CSPC Pharmaceutical Group

Sanofi

Novartis

MSD

Roche

Pfizer

Hengrui Medicine

Hansoh Pharmaceutical Group

GSK

Bristol-Myers Squibb

Abbvie

AstraZeneca

Asta Medica GmbH

Platinum-based Antineoplastic Segment by Type

Oxaliplatin

Cycloplatin

Carboplatin

Lobaplatin

Nedaplatin

Cisplatin

Platinum-based Antineoplastic Segment by Application

Targeted Therapy

Monotherapy

Combination Therapy

Platinum-based Antineoplastic Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Platinum-based Antineoplastic status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Platinum-based Antineoplastic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Platinum-based Antineoplastic significant trends, drivers, influence factors in global and regions.

6. To analyze Platinum-based Antineoplastic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Platinum-based Antineoplastic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Platinum-based Antineoplastic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Platinum-based Antineoplastic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Platinum-based Antineoplastic market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Platinum-based Antineoplastic industry.

Chapter 3: Detailed analysis of Platinum-based Antineoplastic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Platinum-based Antineoplastic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Platinum-based Antineoplastic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Platinum-based Antineoplastic Industry Trends Table 2. Platinum-based Antineoplastic Industry Drivers Table 3. Platinum-based Antineoplastic Industry Opportunities and Challenges Table 4. Platinum-based Antineoplastic Industry Restraints Table 5. Global Platinum-based Antineoplastic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Platinum-based Antineoplastic Revenue Share by Company (2021-2026) Table 7. Global Platinum-based Antineoplastic Sales Volume by Company (Units) & (2021-2026) Table 8. Global Platinum-based Antineoplastic Sales Volume Share by Company (2021-2026) Table 9. Global Platinum-based Antineoplastic Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Platinum-based Antineoplastic Company Ranking, (2024-2026) & (USD Million) Table 11. Global Platinum-based Antineoplastic Key Company Manufacturing Base & Headquarters Table 12. Global Platinum-based Antineoplastic Company, Product Type & Application Table 13. Global Platinum-based Antineoplastic Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Platinum-based Antineoplastic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oxaliplatin Table 18. Significant Companies of Cycloplatin Table 19. Significant Companies of Carboplatin Table 20. Significant Companies of Lobaplatin Table 21. Significant Companies of Nedaplatin Table 22. Significant Companies of Cisplatin Table 23. Global Platinum-based Antineoplastic Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 24. Global Platinum-based Antineoplastic Sales Volume by Type (2021-2026) & (Units) Table 25. Global Platinum-based Antineoplastic Sales Volume by Type (2027-2032) & (Units) Table 26. Global Platinum-based Antineoplastic Sales Volume Share by Type (2021-2026) Table 27. Global Platinum-based Antineoplastic Sales Volume Share by Type (2027-2032) Table 28. Global Platinum-based Antineoplastic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Platinum-based Antineoplastic Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Platinum-based Antineoplastic Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Platinum-based Antineoplastic Sales Value Share by Type (2021-2026) Table 32. Global Platinum-based Antineoplastic Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Targeted Therapy Table 34. Significant Companies of Monotherapy Table 35. Significant Companies of Combination Therapy Table 36. Global Platinum-based Antineoplastic Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 37. Global Platinum-based Antineoplastic Sales Volume by Application (2021-2026) & (Units) Table 38. Global Platinum-based Antineoplastic Sales Volume by Application (2027-2032) & (Units) Table 39. Global Platinum-based Antineoplastic Sales Volume Share by Application (2021-2026) Table 40. Global Platinum-based Antineoplastic Sales Volume Share by Application (2027-2032) Table 41. Global Platinum-based Antineoplastic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Platinum-based Antineoplastic Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Platinum-based Antineoplastic Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Platinum-based Antineoplastic Sales Value Share by Application (2021-2026) Table 45. Global Platinum-based Antineoplastic Sales Value Share by Application (2027-2032) Table 46. Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 47. Global Platinum-based Antineoplastic Sales by Region (2021-2026) & (Units) Table 48. Global Platinum-based Antineoplastic Sales Market Share by Region (2021-2026) Table 49. Global Platinum-based Antineoplastic Sales by Region (2027-2032) & (Units) Table 50. Global Platinum-based Antineoplastic Sales Market Share by Region (2027-2032) Table 51. Global Platinum-based Antineoplastic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Platinum-based Antineoplastic Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Platinum-based Antineoplastic Sales Value Share by Region (2021-2026) Table 54. Global Platinum-based Antineoplastic Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Platinum-based Antineoplastic Sales Value Share by Region (2027-2032) Table 56. Global Platinum-based Antineoplastic Market Average Price (US$/Unit) by Region (2021-2026) Table 57. Global Platinum-based Antineoplastic Market Average Price (US$/Unit) by Region (2027-2032) Table 58. Global Platinum-based Antineoplastic Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 59. Global Platinum-based Antineoplastic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Platinum-based Antineoplastic Sales by Country (2021-2026) & (Units) Table 61. Global Platinum-based Antineoplastic Sales Market Share by Country (2021-2026) Table 62. Global Platinum-based Antineoplastic Sales by Country (2027-2032) & (Units) Table 63. Global Platinum-based Antineoplastic Sales Market Share by Country (2027-2032) Table 64. Global Platinum-based Antineoplastic Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Platinum-based Antineoplastic Sales Value Market Share by Country (2021-2026) Table 66. Global Platinum-based Antineoplastic Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Platinum-based Antineoplastic Sales Value Market Share by Country (2027-2032) Table 68. ChiTaiTianQing Pharmaceutical Group Company Information Table 69. ChiTaiTianQing Pharmaceutical Group Business Overview Table 70. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 72. ChiTaiTianQing Pharmaceutical Group Recent Development Table 73. Simcere Pharmaceutical Company Information Table 74. Simcere Pharmaceutical Business Overview Table 75. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio Table 77. Simcere Pharmaceutical Recent Development Table 78. CSPC Pharmaceutical Group Company Information Table 79. CSPC Pharmaceutical Group Business Overview Table 80. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 82. CSPC Pharmaceutical Group Recent Development Table 83. Sanofi Company Information Table 84. Sanofi Business Overview Table 85. Sanofi Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Sanofi Platinum-based Antineoplastic Product Portfolio Table 87. Sanofi Recent Development Table 88. Novartis Company Information Table 89. Novartis Business Overview Table 90. Novartis Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Novartis Platinum-based Antineoplastic Product Portfolio Table 92. Novartis Recent Development Table 93. MSD Company Information Table 94. MSD Business Overview Table 95. MSD Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. MSD Platinum-based Antineoplastic Product Portfolio Table 97. MSD Recent Development Table 98. Roche Company Information Table 99. Roche Business Overview Table 100. Roche Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Roche Platinum-based Antineoplastic Product Portfolio Table 102. Roche Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer Platinum-based Antineoplastic Product Portfolio Table 107. Pfizer Recent Development Table 108. Hengrui Medicine Company Information Table 109. Hengrui Medicine Business Overview Table 110. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Hengrui Medicine Platinum-based Antineoplastic Product Portfolio Table 112. Hengrui Medicine Recent Development Table 113. Hansoh Pharmaceutical Group Company Information Table 114. Hansoh Pharmaceutical Group Business Overview Table 115. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio Table 117. Hansoh Pharmaceutical Group Recent Development Table 118. GSK Company Information Table 119. GSK Business Overview Table 120. GSK Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. GSK Platinum-based Antineoplastic Product Portfolio Table 122. GSK Recent Development Table 123. Bristol-Myers Squibb Company Information Table 124. Bristol-Myers Squibb Business Overview Table 125. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio Table 127. Bristol-Myers Squibb Recent Development Table 128. Abbvie Company Information Table 129. Abbvie Business Overview Table 130. Abbvie Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Abbvie Platinum-based Antineoplastic Product Portfolio Table 132. Abbvie Recent Development Table 133. AstraZeneca Company Information Table 134. AstraZeneca Business Overview Table 135. AstraZeneca Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. AstraZeneca Platinum-based Antineoplastic Product Portfolio Table 137. AstraZeneca Recent Development Table 138. Asta Medica GmbH Company Information Table 139. Asta Medica GmbH Business Overview Table 140. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio Table 142. Asta Medica GmbH Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Platinum-based Antineoplastic Distributors List Table 146. Platinum-based Antineoplastic Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Platinum-based Antineoplastic Product Image Figure 2. Global Platinum-based Antineoplastic Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 4. Global Platinum-based Antineoplastic Sales (2021-2032) & (Units) Figure 5. Global Platinum-based Antineoplastic Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Platinum-based Antineoplastic Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oxaliplatin Image Figure 10. Cycloplatin Image Figure 11. Carboplatin Image Figure 12. Lobaplatin Image Figure 13. Nedaplatin Image Figure 14. Cisplatin Image Figure 15. Global Platinum-based Antineoplastic Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 16. Global Platinum-based Antineoplastic Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Platinum-based Antineoplastic Sales Volume Share by Type (2021-2032) Figure 18. Global Platinum-based Antineoplastic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Platinum-based Antineoplastic Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Platinum-based Antineoplastic Sales Value Share by Type (2021-2032) Figure 21. Targeted Therapy Image Figure 22. Monotherapy Image Figure 23. Combination Therapy Image Figure 24. Global Platinum-based Antineoplastic Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 25. Global Platinum-based Antineoplastic Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Platinum-based Antineoplastic Sales Volume Share by Application (2021-2032) Figure 27. Global Platinum-based Antineoplastic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Platinum-based Antineoplastic Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Platinum-based Antineoplastic Sales Value Share by Application (2021-2032) Figure 30. Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 31. Global Platinum-based Antineoplastic Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Platinum-based Antineoplastic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Platinum-based Antineoplastic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 35. North America Platinum-based Antineoplastic Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Platinum-based Antineoplastic Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Platinum-based Antineoplastic Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 41. South America Platinum-based Antineoplastic Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Platinum-based Antineoplastic Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Platinum-based Antineoplastic Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Platinum-based Antineoplastic Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Platinum-based Antineoplastic Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Oxaliplatin
  • Cycloplatin
  • Carboplatin
  • Lobaplatin
  • Nedaplatin
  • Cisplatin
Applications
  • Targeted Therapy
  • Monotherapy
  • Combination Therapy
Companies covered
  • ChiTaiTianQing Pharmaceutical Group
  • Simcere Pharmaceutical
  • CSPC Pharmaceutical Group
  • Sanofi
  • Novartis
  • MSD
  • Roche
  • Pfizer
  • Hengrui Medicine
  • Hansoh Pharmaceutical Group
  • GSK
  • Bristol-Myers Squibb
  • Abbvie
  • AstraZeneca
  • Asta Medica GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Platinum-based Antineoplastic Sales Value (2021-2032)
  4. 1.2.2 Global Platinum-based Antineoplastic Sales Volume (2021-2032)
  5. 1.2.3 Global Platinum-based Antineoplastic Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Platinum-based Antineoplastic Market Dynamics
  1. 2.1 Platinum-based Antineoplastic Industry Trends
  2. 2.2 Platinum-based Antineoplastic Industry Drivers
  3. 2.3 Platinum-based Antineoplastic Industry Opportunities and Challenges
  4. 2.4 Platinum-based Antineoplastic Industry Restraints
3 Platinum-based Antineoplastic Market by Company
  1. 3.1 Global Platinum-based Antineoplastic Company Revenue Ranking in 2025
  2. 3.2 Global Platinum-based Antineoplastic Revenue by Company (2021-2026)
  3. 3.3 Global Platinum-based Antineoplastic Sales Volume by Company (2021-2026)
  4. 3.4 Global Platinum-based Antineoplastic Average Price by Company (2021-2026)
  5. 3.5 Global Platinum-based Antineoplastic Company Ranking (2024-2026)
  6. 3.6 Global Platinum-based Antineoplastic Company Manufacturing Base and Headquarters
  7. 3.7 Global Platinum-based Antineoplastic Company Product Type and Application
  8. 3.8 Global Platinum-based Antineoplastic Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Platinum-based Antineoplastic Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Platinum-based Antineoplastic Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Platinum-based Antineoplastic Market by Type
  1. 4.1 Platinum-based Antineoplastic Type Introduction
  2. 4.1.1 Oxaliplatin
  3. 4.1.2 Cycloplatin
  4. 4.1.3 Carboplatin
  5. 4.1.4 Lobaplatin
  6. 4.1.5 Nedaplatin
  7. 4.1.6 Cisplatin
  8. 4.2 Global Platinum-based Antineoplastic Sales Volume by Type
  9. 4.2.1 Global Platinum-based Antineoplastic Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Platinum-based Antineoplastic Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Platinum-based Antineoplastic Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Platinum-based Antineoplastic Sales Value by Type
  13. 4.3.1 Global Platinum-based Antineoplastic Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Platinum-based Antineoplastic Sales Value by Type (2021-2032)
  15. 4.3.3 Global Platinum-based Antineoplastic Sales Value Share by Type (2021-2032)
5 Platinum-based Antineoplastic Market by Application
  1. 5.1 Platinum-based Antineoplastic Application Introduction
  2. 5.1.1 Targeted Therapy
  3. 5.1.2 Monotherapy
  4. 5.1.3 Combination Therapy
  5. 5.2 Global Platinum-based Antineoplastic Sales Volume by Application
  6. 5.2.1 Global Platinum-based Antineoplastic Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Platinum-based Antineoplastic Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Platinum-based Antineoplastic Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Platinum-based Antineoplastic Sales Value by Application
  10. 5.3.1 Global Platinum-based Antineoplastic Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Platinum-based Antineoplastic Sales Value by Application (2021-2032)
  12. 5.3.3 Global Platinum-based Antineoplastic Sales Value Share by Application (2021-2032)
6 Platinum-based Antineoplastic Regional Sales and Value Analysis
  1. 6.1 Global Platinum-based Antineoplastic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Platinum-based Antineoplastic Sales by Region (2021-2032)
  3. 6.2.1 Global Platinum-based Antineoplastic Sales by Region: 2021-2026
  4. 6.2.2 Global Platinum-based Antineoplastic Sales by Region (2027-2032)
  5. 6.3 Global Platinum-based Antineoplastic Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Platinum-based Antineoplastic Sales Value by Region (2021-2032)
  7. 6.4.1 Global Platinum-based Antineoplastic Sales Value by Region: 2021-2026
  8. 6.4.2 Global Platinum-based Antineoplastic Sales Value by Region (2027-2032)
  9. 6.5 Global Platinum-based Antineoplastic Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Platinum-based Antineoplastic Sales Value (2021-2032)
  12. 6.6.2 North America Platinum-based Antineoplastic Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Platinum-based Antineoplastic Sales Value (2021-2032)
  15. 6.7.2 Europe Platinum-based Antineoplastic Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Platinum-based Antineoplastic Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Platinum-based Antineoplastic Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Platinum-based Antineoplastic Sales Value (2021-2032)
  21. 6.9.2 South America Platinum-based Antineoplastic Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Platinum-based Antineoplastic Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Platinum-based Antineoplastic Sales Value Share by Country, 2025 VS 2032
7 Platinum-based Antineoplastic Country-level Sales and Value Analysis
  1. 7.1 Global Platinum-based Antineoplastic Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Platinum-based Antineoplastic Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Platinum-based Antineoplastic Sales by Country (2021-2032)
  4. 7.3.1 Global Platinum-based Antineoplastic Sales by Country (2021-2026)
  5. 7.3.2 Global Platinum-based Antineoplastic Sales by Country (2027-2032)
  6. 7.4 Global Platinum-based Antineoplastic Sales Value by Country (2021-2032)
  7. 7.4.1 Global Platinum-based Antineoplastic Sales Value by Country (2021-2026)
  8. 7.4.2 Global Platinum-based Antineoplastic Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Platinum-based Antineoplastic Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Platinum-based Antineoplastic Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Platinum-based Antineoplastic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ChiTaiTianQing Pharmaceutical Group
  2. 8.1.1 ChiTaiTianQing Pharmaceutical Group Company Information
  3. 8.1.2 ChiTaiTianQing Pharmaceutical Group Business Overview
  4. 8.1.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  6. 8.1.5 ChiTaiTianQing Pharmaceutical Group Recent Developments
  7. 8.2 Simcere Pharmaceutical
  8. 8.2.1 Simcere Pharmaceutical Company Information
  9. 8.2.2 Simcere Pharmaceutical Business Overview
  10. 8.2.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
  12. 8.2.5 Simcere Pharmaceutical Recent Developments
  13. 8.3 CSPC Pharmaceutical Group
  14. 8.3.1 CSPC Pharmaceutical Group Company Information
  15. 8.3.2 CSPC Pharmaceutical Group Business Overview
  16. 8.3.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  18. 8.3.5 CSPC Pharmaceutical Group Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Platinum-based Antineoplastic Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 MSD
  32. 8.6.1 MSD Company Information
  33. 8.6.2 MSD Business Overview
  34. 8.6.3 MSD Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 MSD Platinum-based Antineoplastic Product Portfolio
  36. 8.6.5 MSD Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Roche Platinum-based Antineoplastic Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Platinum-based Antineoplastic Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Hengrui Medicine
  50. 8.9.1 Hengrui Medicine Company Information
  51. 8.9.2 Hengrui Medicine Business Overview
  52. 8.9.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
  54. 8.9.5 Hengrui Medicine Recent Developments
  55. 8.10 Hansoh Pharmaceutical Group
  56. 8.10.1 Hansoh Pharmaceutical Group Company Information
  57. 8.10.2 Hansoh Pharmaceutical Group Business Overview
  58. 8.10.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
  60. 8.10.5 Hansoh Pharmaceutical Group Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 GSK Platinum-based Antineoplastic Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Bristol-Myers Squibb
  68. 8.12.1 Bristol-Myers Squibb Company Information
  69. 8.12.2 Bristol-Myers Squibb Business Overview
  70. 8.12.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Recent Developments
  73. 8.13 Abbvie
  74. 8.13.1 Abbvie Company Information
  75. 8.13.2 Abbvie Business Overview
  76. 8.13.3 Abbvie Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Abbvie Platinum-based Antineoplastic Product Portfolio
  78. 8.13.5 Abbvie Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Asta Medica GmbH
  86. 8.15.1 Asta Medica GmbH Company Information
  87. 8.15.2 Asta Medica GmbH Business Overview
  88. 8.15.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
  90. 8.15.5 Asta Medica GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Platinum-based Antineoplastic Value Chain Analysis
  2. 9.1.1 Platinum-based Antineoplastic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Platinum-based Antineoplastic Sales Mode & Process
  6. 9.2 Platinum-based Antineoplastic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Platinum-based Antineoplastic Distributors
  9. 9.2.3 Platinum-based Antineoplastic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst